Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease

Table 1 Steatotic liver disease, new classification

Subcategories	Etiologies
MASLD	Presence of hepatic steatosis and 1 cardiometabolic risk factor out of 5 (see Table 2) and no other discernible cause for hepatic steatosis. If additional drivers of steatosis are identified, then this is consistent with a combination etiology
MetALD	MASLD and increased alcohol intake: 20-50 g/day (females); 30-60 g/day (males)
Alcohol Associated (Alcohol related liver disease-ALD)	Alcohol intake > 50 g/day (females) and > 60 g/day (males)
Specific etiology SLD	(1) Drug-induced liver injury; (2) Monogenic diseases: Lysosomal acid lipase deficiency, Wilson disease, hypo-betalipoproteinemia, inborn errors of metabolism; and (3) Miscellaneous: Celiac disease, HIV, malnutrition, HCV
Cryptogenic SLD	Those with no identifiable cause (cryptogenic SLD) may be re-categorized in the future pending developments in our understanding of disease pathophysiology

MASLD: Metabolic dysfunction-associated steatotic liver disease; MetALD: Metabolic and alcohol related/associated liver disease; ALD: Alcohol related liver disease; SLD: Steatotic liver disease; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus.